Ethylene Dibromide (1,2 Dibromoethane)

An effective soil fumigant, insecticide, and nematocide. In humans, it causes severe burning of skin and irritation of the eyes and respiratory tract. Prolonged inhalation may cause liver necrosis. It is also used in gasoline. Members of this group have caused liver and lung cancers in rodents. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), 1,2-dibromoethane may reasonably be anticipated to be a carcinogen.

Also Known As:

Networked: 55 relevant articles (1 outcomes, 5 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Dange, Deepak: 1 article (05/2022)
2.	Garg, Palak: 1 article (05/2022)
3.	Jiang, Yixiao: 1 article (05/2022)
4.	Jones, Cameron: 1 article (05/2022)
5.	Feng, Yunxia: 1 article (10/2020)
6.	Gao, Shaohua: 1 article (10/2020)
7.	Jia, Runzhong: 1 article (10/2020)
8.	Li, Bo: 1 article (10/2020)
9.	Shi, Ning: 1 article (10/2020)
10.	Xiao, Anshan: 1 article (10/2020)

Related Diseases

1.	Dehydration (Water Stress) 04/01/1975 - "Elimination of Criconemoides xenoplax from a prune orchard soil by fumigation with ethylene dibromide at the rate of 42 muliter/liter of soil (equivalent to about 13 gal/acre) improved the growth of Myrobalan plum, Addition of this nematode to Myrobalan seedlings or young 'Marianna 2624' plants propagated from cuttings resulted in destruction of cortical root tissue, darkening of roots, alteration of water stress, lowering of nutrient levels in leaves, and reduction in plant weight. "
2.	Neoplasms (Cancer) 06/01/1988 - "Cancer risks for ethylene dibromide (EDB) were estimated by fitting several linear non-threshold additive models to data from a gavage bioassay. " 03/01/1985 - "The negligible role of ethylene dibromide in overall human cancer risk." 02/01/2018 - "The calculation of cancer risk values showed that seventeen compounds were higher than acceptable limit amongst which 1,2-dibromoethane had maximum values of 1.27 × 10-2 to 3.24 × 10-2 for WBPs; for SBPs, all quantified compounds exceeded the acceptable limit, and 82.61% VOCs were distributed in a scope larger than 1 × 10-3. Additionally, a removal efficiency of 60% was considered for primary receptor with personal protective equipment, and subsequent results confirmed its inability of lowering the risk resulted from hazardous VOCs. " 01/01/2017 - "An inhalation unit risk factor (URF) was developed for ethylene dibromide (EDB, CAS 106-93-4) based on an increased incidence of nasal cavity adenocarcinomas observed in female rats in a 2-year inhalation cancer bioassay conducted by the National Toxicology Program (NTP). " 01/01/1980 - "EDB (ethylene dibromide) is of regulatory interest because it has cancer inducing properties and is a causative agent of aspermia. "
3.	Carcinogenesis 03/01/1982 - "Carcinogenesis Bioassay of 1,2-Dibromoethane (CAS No. 106-93-4) in F344 Rats and B6C3F1 Mice (Inhalation Study)." 04/01/1979 - "Technical background information report on carcinogenesis bioassay of 1,2-dibromoethane (EDB)." 02/01/1979 - "Report on carcinogenesis bioassay of 1,2-dibromoethane (EDB)." 02/01/1996 - "Results gave evidence for a promoting role of 1,2-dibromoethane in multistep carcinogenesis, probably responsible for the higher oncogenic ability of this compound with respect to 1,1,2,2-tetrachloroethane." 03/01/1982 - "A carcinogenesis bioassay of 1,2-dibromoethane, a widely used nematocide and leaded gasoline additive, was conducted by exposing groups of 50 F344 rats and B6C3F1 mice of each sex by inhalation to concentrations of 10 or 40 ppm of the 1,2-dibromoethane for 78-103 weeks. "
4.	Hyperplasia 03/01/1982 - "Exposure to 1,2-dibromoethane was also associated with hepatic necrosis and toxic nephropathy in rats of either sex, testicular degeneration in male rats, retinal degeneration in female rats, and epithelial hyperplasia of the respiratory system in mice. " 06/01/1993 - "We show here that whereas c-fos and c-jun expression increased soon after partial hepatectomy or carbon tetrachloride administration, an increased expression of c-jun in the absence of c-fos expression occurred during direct hyperplasia induced by lead nitrate and ethylene dibromide. " 05/01/1990 - "Experiments were designed to investigate the expression of three cell-cycle-dependent proto-oncogenes in response to two different types of proliferative stimuli: compensatory cell proliferation after partial hepatectomy (PH) or CCl4 and liver hyperplasia induced by the mitogens ethylene dibromide (EDB) and cyproterone acetate (CPA). " 05/01/1990 - "After a 2-week recovery period liver cell proliferation was repeatedly induced by four or eight necrogenic doses of carbon tetrachloride (compensatory cell proliferation), or by four or eight treatments with three different liver mitogens, namely lead nitrate, ethylene dibromide and nafenopin (direct hyperplasia). " 06/01/1993 - "The steady-state levels of c-fos, c-jun and c-myc messenger RNA were investigated in rat liver tissue after proliferative stimuli of different nature-namely, compensatory regeneration induced by partial hepatectomy or carbon tetrachloride administration-and direct hyperplasia induced by four different hepatomitogens: lead nitrate, ethylene dibromide, cyproterone acetate and nafenopin. "
5.	Poisoning 10/01/2013 - "Ethylene dibromide (EDB) poisoning is very common in Central India and has fatal outcome. " 12/01/2007 - "Prospectively collected data of sixty four patients with ethylene dibromide poisoning were reviewed. " 12/01/2007 - "In view of high incidence and mortality due to ethylene dibromide poisoning, a prospective study was planned to assess demographic, toxicological, clinical profile and outcome. " 04/01/2001 - "Two cases of ethylene dibromide poisoning." 11/01/1988 - "Ethylene dibromide (EDB) poisoning."

Related Drugs and Biologics

1.	Benzene (Benzole)
2.	Nafenopin
3.	Mitogens
4.	Epichlorohydrin (Epichlorhydrin)
5.	Carcinogens
6.	1,2-dibromo-3-chloropropane (DBCP)
7.	Cyproterone Acetate
8.	lead nitrate
9.	1,3-butadiene (divinyl)
10.	propylene oxide

Related Therapies and Procedures

1.	Hepatectomy
2.	Plasma Exchange
3.	Oral Administration
4.	Personal Protective Equipment